Physician profile
John Sharon
NPI 1770576860
$1,260.09
in general payments reported to CMS, 2019-2025
13 companies · $36.90 in 2025
The $36.90 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $202 · 2021: $156 · 2022: $324 · 2023: $290 · 2024: $102 · 2025: $36.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.83 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $577.45 | 2019-2023 | Myrbetriq, Veozah |
| Abbvie INC. | $345.71 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Evofem Biosciences, INC. | $75.86 | 2021-2022 | |
| Pfizer INC. | $57.32 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $39.23 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $37.52 | 2024 | Myfembree |
| Biohaven Pharmaceuticals, INC. | $24.67 | 2021 | |
| Hologic Sales and Service, LLC | $20.43 | 2023 | Aptima, Thinprep 2000 Processor |
| Virtus Pharmaceuticals LLC | $20.09 | 2021 | |
| Novo Nordisk INC | $19.12 | 2025 | Wegovy |
| Millicent US INC | $18.23 | 2024 | Intrarosa |
| Myovant Sciences INC. | $12.74 | 2021 | |
| Agile Therapeutics, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sharon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.